Abstract:Rationale: Genome editing by CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 is evolving rapidly. Recently, second-generation CRISPR/Cas9 activation systems based on nuclease inactive dead (d)Cas9 fused to transcriptional transactivation domains were developed for directing specific guide (g)RNAs to regulatory regions of any gene of interest, to enhance transcription. The application of dCas9 to activate cardiomyocyte transcription in targeted genomic loci in vivo has not been demonstrated so far. Objective: We aimed to develop a mouse model for cardiomyocyte-specific, CRISPR-mediated transcriptional modulation, and to demonstrate its versatility by targeting Mef2d and Klf15 loci (2 well-characterized genes implicated in cardiac hypertrophy and homeostasis) for enhanced transcription. Methods and results: A mouse model expressing dCas9 with the VPR transcriptional transactivation domains under the control of the Myh (myosin heavy chain) 6 promoter was generated. These mice innocuously expressed dCas9 exclusively in cardiomyocytes. For initial proof-of-concept, we selected Mef2d, which when overexpressed, led to hypertrophy and heart failure, and Klf15, which is lowly expressed in the neonatal heart. The most effective gRNAs were first identified in fibroblast (C3H/10T1/2) and myoblast (C2C12) cell lines. Using an improved triple gRNA expression system (TRISPR [triple gRNA expression construct]), up to 3 different gRNAs were transduced simultaneously to identify optimal conditions for transcriptional activation. For in vivo delivery of the validated gRNA combinations, we employed systemic administration via adeno-associated virus serotype 9. On gRNA delivery targeting Mef2d expression, we recapitulated the anticipated cardiac hypertrophy phenotype. Using gRNA targeting Klf15, we could enhance its transcription significantly, although Klf15 is physiologically silenced at that time point. We further confirmed specific and robust dCas9VPR on-target effects. Conclusions: The developed mouse model permits enhancement of gene expression by using endogenous regulatory genomic elements. Proof-of-concept in 2 independent genomic loci suggests versatile applications in controlling transcription in cardiomyocytes of the postnatal heart.

Phase-separated DropCRISPRa platform for efficient gene activation in mammalian cells and mice

Generation and validation of versatile inducible CRISPRi embryonic stem cell and mouse model

CRISPR-Mediated Activation of Endogenous Gene Expression in the Postnatal Heart

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Programmable DNA Repair with CRISPRa/i Enhanced Homology-Directed Repair Efficiency with a Single Cas9

Programmable Transcriptional Modulation with a Structured RNA-Mediated CRISPR-dCas9 Complex

MiniCAFE, a CRISPR/Cas9-based compact and potent transcriptional activator, elicits gene expression in vivo

Scaffold-based non-viral CRISPR delivery platform for efficient and prolonged gene activation to accelerate tissue regeneration

Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system

Large genomic fragment deletion and functional gene cassette knock-in via Cas9 protein mediated genome editing in one-cell rodent embryos

Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex

Highly efficient and specific regulation of gene expression using enhanced CRISPR-Cas12f system

Multiplexed Genome Regulation in Vivo with Hyper-Efficient Cas12a

In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation

Abstract 5607: A highly efficient donor system for CRISPR knock-in editing

Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing

Specific multivalent molecules boost CRISPR-mediated transcriptional activation

Highly efficient CRISPR-mediated genome editing through microfluidic droplet cell mechanoporation

A synthetic transcription platform for programmable gene expression in mammalian cells

Optimized Strategy for in Vivo Cas9-activation in Drosophila

A CRISPR/RfxCas13d-mediated strategy for efficient RNA knockdown in mouse embryonic development